Home
About BEB
Curriculum
Admission
CNC Research
BEB in the Media
 
 
PRINCIPLES AND PRACTICE IN DRUG DEVELOPMENT I MIT-PORTUGAL PROGRAM 2015/2016
 
April 4 - 15
João Nuno Moreira, Luís Pereira de Almeida, Sérgio Simões, Stan Finkelstein
MIT-PORTUGAL PROGRAM 2015/2016
PRINCIPLES AND PRACTICE IN DRUG DEVELOPMENT - ELECTIVE COURSE
Center for Neuroscience and Cell Biology (CNC) - University of Coimbra


April 4 - April 15, 2016

João Nuno Moreira, Luís Pereira de Almeida, Sérgio Simões, Stan Finkelstein

Local: CNC auditorium (Polo I)

NOTE:
last minute changes to the program might take place.

April 4 - Monday
10.00 h - Introduction to the course
João Nuno Moreira I PhD (CNC and Faculty of Pharmacy, University of Coimbra)
Luís Pereira de Almeida I PhD (CNC and Faculty of Pharmacy, University of Coimbra)
Sérgio Simões I PhD (CNC and Faculty of Pharmacy, University of Coimbra)
Stan N. Finkelstein I MD, PhD (Senior Research Assistant in the MIT Engineering Systems Division and Associate Professor of Medicine at Harvard Medical School)

11.00 h - The Pharmaceutical Industry and the Drug Development Process
Stan N. Finkelstein I MD, PhD (Senior Research Scientist in the MIT Engineering Systems Division and Associate Professor of Medicine, Harvard Medical School)

14.00 h - Basic Science I – Discovery Innovation and Emerging Technologies; Basic Business
Anthony J. Sinskey I PhD (Professor of Biology at MIT)

16.00 h - Building predictive models for oncology drug discovery
Darrin Stuart I PhD (Director, Cell Biology/Small Molecule Drug Discovery, Novartis Institutes for Biomedical Research, Cambridge, USA)

April 5 - Tuesday
09.30 h - FDA Process, Off-Label Prescribing, Insurance Coverage
Stan N. Finkelstein I MD, PhD (Senior Research Assistant in the MIT Engineering Systems Division and Associate Professor of Medicine at Harvard Medical School)

16:30 h - Building Merrimack Therapeutics
Robert Mulroy I CEO of Merrimack Therapeutics

April 6 - Wednesday
10.00 h - Modeling chemistry and biology in drug discovery
Nuno Palma I PhD (BIAL, Indústria Farmacêutica, Portugal)

11.30 h - Development of small molecule inhibitors for treatment of CNS disorders
Laszlo Kiss I PhD (BIAL, Indústria Farmacêutica, Portugal)

14.30 h - Pharmacology and toxicology of new chemical entities
Lyndon C. Wright I PhD (BIAL, Indústria Farmacêutica, Portugal)

16:00 h - Clinical development of new chemical entities
Ana Santos I BSc (BIAL, Indústria Farmacêutica, Portugal)

April 7 - Thursday
9.30 h - Bluepharma Pharmaceutical Industry SA: from development of generics to innovative research
Sérgio Simões I PhD
10.30 h - Bluepharma Pharmaceutical Industry SA: from development of generics to innovative research - site visit
(Bluepharma address: Rua Bayer, 3045-016 São Martinho do Bispo - Coimbra; suggested transportation: bus no. 6, in front of the University Hospital or at Praça da República, http://www.smtuc.pt/avisos/index.php?id=490)

16.30 h - Technology transfer – the perspective from MIT
Aaron D Schwartz I Licensing officer at the MIT TLO

April 8 - Friday
09.30 h - Photodynamic therapy in oncology
Cláudia Silva I PhD (Luzitin, SA)

14.30 h - The Role of Quality by Design in the Pharmaceutical Industry
Filipe Neves I PhD (Director of manufacturing scale-up, Hovione, Portugal)

April 11 – Monday
10.00 h - Some issues in drug development: discussion of case studies
Miguel Prazeres I PhD (Instituto Superior Técnico, Technical University of Lisbon)

14.00 h - Visit to Biocant Park – Innovation Center in Biotechnology
(hired bus; meeting point: main entrance of CNC building, in front of the Department of Physics)

April 12 - Tuesday
10.30 h - Regulatory Affairs – the european perspective
Rogério Gaspar I PhD (iMed.UL and Faculty of Pharmacy, University of Lisbon)

14:30 - Toxicology of new drug entities
Beatriz Lima I EMA

April 13 - Wednesday
9.30 h - Nanotechnology for drug targeting and the impact on drug development
João Nuno Moreira I PhD
Vera Moura I PhD (CEO of TREAT U, SA and CNC)
Nuno Fonseca  I PhD (CNC)

16.00 h - New trends in immunotherapy
Daniel Lopes de Menezes I PhD (Biological Discovery California, Bristol-Myers Squibb)

April 14 - Thursday

9.30 h - Nanotechnology for drug and gene targeting and the impact on drug development (cont.)
Luís Pereira de Almeida I PhD (CNC)
Clévio Nóbrega I PhD (CNC)
Rui Nobre I PhD (CNC)
Liliana Mendonça I PhD (CNC)

16.00 h - Moderna Therapeutics: Moderna´s ventures as a launch-point for each diverse drug development model
Evan Rachlin I MD, MBA, Senior Director of Strategic Planning (Moderna Therapeutics, Cambridge, MA, USA)

April 15 – Friday
9 h - Students´ presentations
back
 
© 2017 BEB - Doctoral Programme in Experimental Biology and Biomedicine powered by ponto.C